Cover Image
市場調查報告書

脂漏性皮膚炎:開發平台分析

Seborrhea - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200996
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
脂漏性皮膚炎:開發平台分析 Seborrhea - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 40 Pages
簡介

脂漏性皮膚炎是主要作用於頭皮的一般性皮膚病,會發生脫屑和發癢,發炎,頭皮屑等症狀。發生在嬰兒身上則會特別稱之為新生兒頭部皮膚炎(乳痂)。脂漏性皮膚炎也會影響臉部和胸部、背部等人體各處皮脂腺。

本報告提供全球各國治療脂漏性皮膚炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

脂漏性皮膚炎概要

治療藥的開發

  • 脂漏性皮膚炎開發中產品:概要
  • 脂漏性皮膚炎開發中產品:比較分析

各企業開發中的脂漏性皮膚炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

脂漏性皮膚炎治療藥:開發中的產品一覽(各企業)

脂漏性皮膚炎開發治療藥的企業

  • Aclaris Therapeutics, Inc.
  • Biomar Microbial Technologies
  • EpiPharm AG
  • Maruho
  • Phosphagenics Limited

脂漏性皮膚炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Product-10156
  • Product-49778
  • lanoconazole
  • NCX-1047
  • 抑制痤瘡·脂漏性皮膚炎的SCD-1小分子
  • 脂肪漏性皮膚炎用醫藥品
  • IB-07-A-085
  • IB-07A081

脂漏性皮膚炎治療藥:最新的藥物簡介

脂漏性皮膚炎治療藥:開發暫停的產品

脂漏性皮膚炎治療藥:開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8383IDB

Summary

Global Markets Direct's, 'Seborrhea - Pipeline Review, H2 2016', provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seborrhea
  • The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
  • The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seborrhea

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Seborrhea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Seborrhea Overview
  • Therapeutics Development
    • Pipeline Products for Seborrhea - Overview
  • Seborrhea - Therapeutics under Development by Companies
  • Seborrhea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Seborrhea - Products under Development by Companies
  • Seborrhea - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics Inc
    • Amorepacific Corporation
    • Biomar Microbial Technologies
    • EpiPharm AG
    • Phosphagenics Limited
  • Seborrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • artemether - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-07A081 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-07A085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Seborrhea - Dormant Projects
  • Seborrhea - Discontinued Products
  • Seborrhea - Product Development Milestones
    • Featured News & Press Releases
      • Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs
      • Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis
      • Mar 17, 2015: Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor
      • Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor
      • Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Seborrhea, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2016
  • Seborrhea - Pipeline by Amorepacific Corporation, H2 2016
  • Seborrhea - Pipeline by Biomar Microbial Technologies, H2 2016
  • Seborrhea - Pipeline by EpiPharm AG, H2 2016
  • Seborrhea - Pipeline by Phosphagenics Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Seborrhea - Dormant Projects, H2 2016
  • Seborrhea - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Seborrhea, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top